- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01656889
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA).
This research is being done to compare the efficacy of HP802-247 plus compression therapy against Vehicle plus compression therapy in achieving complete wound closure over the 12-week treatment period. Vehicle looks the same as HP802-247 but contains no cells.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancovuer, British Columbia, Canada, V5Z1M9
-
-
Ontario
-
Hamilton, Ontario, Canada, L8R2R3
-
London, Ontario, Canada, N6C5J1
-
Sudbury, Ontario, Canada, P3E5J1
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H5N4
-
-
-
-
Arizona
-
Glendale, Arizona, United States, 85306
-
Phoenix, Arizona, United States, 85012
-
Phoenix, Arizona, United States, 85006
-
Tucson, Arizona, United States, 85724
-
Tucson, Arizona, United States, 85723
-
-
California
-
Carlsbad, California, United States, 92009
-
Castro Valley, California, United States, 94546
-
Fresno, California, United States, 93720
-
Laguna Hills, California, United States, 92653
-
Long Beach, California, United States, 90822
-
Los Angeles, California, United States, 90095
-
San Diego, California, United States, 92013
-
San Francisco, California, United States, 94115
-
Stockton, California, United States, 95204
-
Sylmar, California, United States, 91342
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
-
-
Florida
-
Gainesville, Florida, United States, 32605
-
Hialeah, Florida, United States, 33013
-
Miami, Florida, United States, 33125
-
South Miami, Florida, United States, 33143
-
Tamarac, Florida, United States, 33321
-
-
Illinois
-
Chicago, Illinois, United States, 60611
-
Chicago, Illinois, United States, 60612
-
Chicago, Illinois, United States, 60616
-
Jacksonville, Illinois, United States, 62650
-
North Chicago, Illinois, United States, 60064
-
Springfield, Illinois, United States, 62702
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
-
Cambridge, Massachusetts, United States, 02138
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
-
-
New Jersey
-
Emerson, New Jersey, United States, 07630
-
-
New York
-
New York, New York, United States, 10025
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
-
-
Ohio
-
Akron, Ohio, United States, 44307
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74127
-
-
Pennsylvania
-
Dunmore, Pennsylvania, United States, 18512
-
Wyomissing, Pennsylvania, United States, 19610
-
-
Texas
-
Dallas, Texas, United States, 75390
-
Fort Worth, Texas, United States, 76104
-
Fort Worth, Texas, United States, 76107
-
San Antonio, Texas, United States, 78229
-
-
Utah
-
St. George, Utah, United States, 84770
-
-
Virginia
-
Roanoke, Virginia, United States, 24013
-
-
Washington
-
Tacoma, Washington, United States, 98431
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide informed consent.
- Age ≥ 18 years and of either sex.
- Willing to comply with protocol instructions, including allowing all study assessments.
- Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area ≥ 2.0 cm2 and ≤ 12.0 cm2
- Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence.
- Arterial supply adequacy confirmed
- Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone.
- Target ulcer duration ≥ 6 weeks but ≤ 104 weeks (24 months).
- Acceptable state of health and nutrition
Exclusion Criteria:
- History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin B.
- Prior diagnosis of Systemic Lupus Erythematosus with elevated anti-DNA antibody titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication.
- Therapy with another investigational agent within thirty (30) days of Screening, or during the study.
- A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic).
- Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit.
- Refusal of or inability to tolerate compression therapy.
- Therapy of the target ulcer with autologous skin graft, Apligraf™, or Dermagraft™ within 30 days preceding the Screening Visit.
- History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers).
- Any prior exposure to HP802-247 or its vehicle.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HP802-247
HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
|
HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
|
PLACEBO_COMPARATOR: Vehicle
Vehicle Control (fibrinogen solution & thrombin solution without cells)
|
(fibrinogen solution & thrombin solution without cells)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the Treatment Groups for the Proportion of Subjects With Complete Wound Closure Over the 12-Week Treatment Period From Baseline
Time Frame: 12 Weeks
|
For each treatment group the area of each subject's target ulcer was measured on a weekly basis, for up to 12 weeks, using a laser-based wound imaging system in conjunction with software to measure area.
Following initial closure subjects returned for four weekly visits to confirm wound closure.
Wounds that remained closed for four weeks were classified as confirmed closures; if a wound opened at any of the 4 visits it was not considered to have closed.
For subjects who dropped from the study, their remaining visit values were imputed using LOCF; wound status of closed was not imputed.
|
12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the Efficacy of the Treatment Groups in Achieving Complete Wound Closure, Based on Time in Days to Closure Over the 12-Week Treatment Period From Baseline.
Time Frame: 12 Weeks
|
This key secondary outcome was based on a Cox Proportional Hazard Analysis and a Kaplan-Meier survival analysis.
|
12 Weeks
|
Compare the Treatment Groups for the Percentage of Closed Ulcers at Each Visit of the 12-Week Treatment Period From Baseline
Time Frame: Weekly, over the 12 week treatment period, or until wound closure, which ever occurred first
|
Treatment groups were compared for the proportion of wounds closed at each weekly visit.
For subjects who dropped from the study, their remaining visit values were imputed using LOCF.
|
Weekly, over the 12 week treatment period, or until wound closure, which ever occurred first
|
Number of Subjects With Durable Wound Healing Over the 3 Months Following Complete Wound Closure
Time Frame: Target ulcer status observed at two and three months following initial ulcer closure.
|
Subjects who completed the treatment period with confirmed wound closure were followed in the post-treatment period for a further two months to determine their closed wound status (remained closed/reopened), giving a measure of persistence of wound closure following completion of treatment.
|
Target ulcer status observed at two and three months following initial ulcer closure.
|
Change in Pain Associated With the Target Leg at Each of the 12 Double Blind Treatment Weeks
Time Frame: Weekly, over the 12 week treatment period, baseline
|
Target leg pain were measured using a Visual Analog Scale [Range: 0mm - 100mm].
Subjects marked their pain level on a 100 mm horizontal line, with a short vertical line across the scale, 0 denoting no pain and 100mm the maximum pain.
|
Weekly, over the 12 week treatment period, baseline
|
Change in Target Ulcer Pain
Time Frame: Weekly, over 12 week treament period, baseline
|
Target ulcer pain were measured using a Visual Analog Scale [Range: 0mm - 100mm].
Subjects marked their pain level on a 100 mm horizontal line, with a short vertical line across the scale, 0 denoting no pain and 100mm the maximum pain.
|
Weekly, over 12 week treament period, baseline
|
Compare the Efficacy of the Treatment Groups in Achieving Complete Wound Closure, Based on the Median Time (in Days) to Closure Over the 12-Week Treatment Period From Baseline.
Time Frame: 12 weeks
|
This key secondary outcome was based on a Kaplan-Meier survival analysis.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 802-247-09-029
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcers
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
HealthpointCompletedVenous Leg Ulcer | Venous Stasis UlcersUnited States, Canada
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
Oneness Biotech Co., Ltd.Taipei Veterans General Hospital, Taiwan; Taipei Medical University Shuang...RecruitingVenous Leg Ulcers (VLU)Taiwan
-
University of TurkuUnknown
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
Macrocure Ltd.UnknownChronic Venous Leg UlcersUnited States
Clinical Trials on HP-802-247
-
HealthpointTerminatedVenous Leg UlcersUnited States
-
Jubilant Therapeutics Inc.RecruitingMetastatic Solid Tumor | Locally Advanced Solid TumorUnited States
-
HealthpointCompletedNormal Female VolunteersUnited States
-
HealthpointTerminatedUlcer | Venous Ulcer | Venous Stasis UlcerGermany, Poland, Belgium, Czech Republic, Hungary
-
HealthpointUnknownVenous Leg UlcerUnited States, Canada
-
Fundació Institut de Recerca de l'Hospital de la...Programa de Reproducción Asistida F. Puigvert - HSCSPTerminatedPolycystic Ovary SyndromeSpain
-
Baxalta now part of ShireBaxalta Innovations GmbH, now part of ShireTerminatedHemophilia ANetherlands, Spain, Italy, Turkey, Bulgaria, United States, Canada, Germany, Norway, Poland, Russian Federation, South Africa
-
LG ChemCompletedInfertility, FemaleKorea, Republic of
-
HK inno.N CorporationAsan Medical CenterCompleted
-
HealthpointCompletedVenous Leg UlcersUnited States, Canada, Puerto Rico